WaveMan
WaveMan · Company
QTRX · Quanterix Corp
> Search tickers & screens ⌘K
LIVE
← All companies

QTRX Quanterix (QTRX) Insider Trading, Ownership & Congress Trades

Medical Devices · Laboratory analytical instruments · CIK 0001503274
Quote by TradingView
C-suite buying · 1
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
80
13F, latest reported quarter
Conversions, 180 days
45
Codes C/M, not in net · no price filed

What the filings say about QTRX

Insiders, 180 days
+$296.0K net bought
2 buyers

Quanterix insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Quanterix Corp insiders bought a net $296.0K of stock across 144 Form 4 purchases and sales, with 2 insiders buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
DONNELLY WILLIAM P
Director
BUY
2026-08-14 SECtraded 2026-08-13
72,245
$211.7K
-3.1%
Context
  • 3 earlier Form 4 trades (code P or S) here by this insider (3 buys), the last on Aug 12, 2026.
  • -13.4% median (-13.4% mean) 90-day return after 2 previous buys.
  • The trade is 72.7% of the 99,400 shares held after it.
  • No other insider bought within 30 days.
  • 80 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director DONNELLY WILLIAM P bought about $211.7K of QTRX on Aug 13, 2026, the largest insider purchase at the company since 2025; 80 funds added in the latest 13F quarter.
DONNELLY WILLIAM P
Director
BUY
2026-08-14 SECtraded 2026-08-12
27,155
$74.7K
-3.1%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (2 buys), the last on Jun 6, 2025.
  • -13.4% median (-13.4% mean) 90-day return after 2 previous buys.
  • The trade is 100.0% of the 27,155 shares held after it.
  • No other insider bought within 30 days.
  • 80 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director DONNELLY WILLIAM P bought about $74.7K of QTRX on Aug 12, 2026, the largest insider purchase at the company since 2025; 80 funds added in the latest 13F quarter.
Meadows Benjamin
Chief Commercial Officer
BUY
2026-06-12 SECtraded 2026-05-12
3,500
$9.7K
-8.7%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 100.0% of the 3,500 shares held after it.
  • No other insider bought within 30 days.
  • 80 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Commercial Officer Meadows Benjamin bought about $9.7K of QTRX on May 12, 2026; 80 funds added in the latest 13F quarter.
Sriram Vandana
Chief Financial Officer
BUY
2025-09-17 SECtraded 2025-09-12
4,150
$19.9K
-49.3%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 4.8% of the 87,200 shares held after it.
  • No other insider bought within 30 days.
  • 80 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Sriram Vandana bought about $19.9K of QTRX on Sep 12, 2025; 80 funds added in the latest 13F quarter.
WALT DAVID R
Director
BUY
2025-06-13 SEC
123,990
$761.3K
-54.1%
Context
  • 5 earlier Form 4 trades (code P or S) here by this insider (5 buys), the last on Jun 12, 2025.
  • -15.4% median (-13.3% mean) 90-day return after 5 previous buys.
  • The trade is 6.6% of the 1,866,933 shares held after it.
  • 2 other insiders bought within 30 days.
  • 80 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director WALT DAVID R bought about $761.3K of QTRX on Jun 13, 2025, the largest insider purchase at the company since 2022; 2 other insiders bought within 30 days and 80 funds added in the latest 13F quarter.
144 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 139 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net +$296.0K over 180 days
+$286.4K over 90 days
more than 83% of Medical Devices
Congress
no House purchase disclosed in the last 12 months
Funds
80 funds bought in last quarter
more than 57% of Medical Devices
Revenue
+1.1% year over year
below 75% of Medical Devices
Margin
-77.1% net margin
below 77% of Medical Devices
Buybacks
no share repurchases reported
Short interest
12.3% of the float short (float per yahoo 2026-10-27) · 8.4 days to cover · settled 2026-10-15
more than 87% of Medical Devices
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch QTRX

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-51.7%12M
-59%-27%+5%+38%2025-102025-122026-022026-042026-062026-082026-10 2026-08-13 · DONNELLY WILLIAM P bought $211.7K2026-08-12 · DONNELLY WILLIAM P bought $74.7K2026-05-12 · Meadows Benjamin bought $9.7K
Insider buy
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns QTRX: institutional holders (13F)

13F holdings, latest reported quarter
First Eagle Investment Management, LLC
5,506,330 sh
$23.8M
BlackRock, Inc.
3,635,411 sh
$15.7M
Blue Water Life Science Advisors, LP
3,474,202 sh
$15.0M
Portolan Capital Management, LLC
1,899,308 sh
$8.2M
VANGUARD CAPITAL MANAGEMENT LLC
1,800,644 sh
$7.8M

Congress trades in QTRX

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

QTRX planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

QTRX mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
First Eagle Small Cap Opportunity Fund
$9.5M position · as of 2026-07-31
0.3%
Ultra-Small Company Market Fund
$294.7K position · as of 2026-06-30
0.2%
Invesco NASDAQ Future Gen 200 ETF
$35.9K position · as of 2026-05-31
0.2%
Columbia Variable Portfolio - Small Cap Value Discovery Fund
$538.5K position · as of 2026-06-30
0.1%
Columbia Small Cap Value Discovery Fund
$2.4M position · as of 2026-07-31
0.1%
AQR Small Cap Multi-Style Fund
$355.0K position · as of 2026-06-30
0.1%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders are net buyers of their own stock.
The record shows a net $296.0K bought by insiders over 180 days, 80 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
PENBLFSMTDSIBNWRBYISRGTXGDXCMEWTMDXOMIRMD

QTRX financials

Revenue growth
+1.1%
XBRL, annual
Net margin
-77.1%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$153.4M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
-80.3%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
-$81.7M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
0.01x
LongTermDebt as filed 2021-09-30 (57 months older than the period end) (includes the current portion); equity 2026-06-30
Cash flow to debt
-41.65x
TTM operating cash flow over LongTermDebt as filed 2021-09-30 (57 months older than the period end) (includes the current portion)
Return on equity
-46.5%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-35.4%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on capital employed
-51.2%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
$91.6M
market value at close 2026-10-26 on 2026-08-03 shares, plus LongTermDebt as filed 2021-09-30 (57 months older than the period end) (includes the current portion), minus cash 2026-06-30
FCF yield
-61.0%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122023-09
Revenue$138.9M$137.4M$122.4Mn/a
Gross profit$65.0M$83.1M$74.2Mn/a
Operating income-$125.5M-$52.6M-$46.0Mn/a
Net income-$107.2M-$38.5M-$28.4Mn/a
EPS (diluted)-2.51-1.00-0.75n/a
Operating cash flow-$77.2M-$35.2M-$18.8Mn/a
Cash$29.8M$56.7M$174.4M$201.3M
SEC XBRL, fiscal years, as known on 2026-10-28

QTRX Stock Sonar score 6/7 axes

Find similar shapesCompare

QTRX ranks highest on insider conviction (78th percentile) and institutional and government (57th), and lowest on profitability (35th), among Medical Devices peers.

ProfitHealthGrowthInsidersInstitutionsRisk
Profitability
35
Inputs
  • Return on equity-46.5% · 39 pct, sector of 183
  • Return on assets-35.4% · 36 pct, sector of 214
  • Return on invested capitalpre-tax loss, no effective tax rate to apply
  • Return on capital employed-51.2% · 31 pct, sector of 188
Financial health
45
Inputs
  • Debt to equity0.01x · 87 pct, sector of 159
  • Cash flow to debt-41.65x · 4 pct, sector of 150
Growth
56
Inputs
  • Revenue growth, YoY+1.1% · 25 pct, sector of 219
  • Backlog growth, YoY+65.7% · 86 pct, sector of 37
Insider conviction
78
Inputs
  • Net Form 4 buying (codes P and S), 180d$296K · 83 pct, sector of 140
  • Insider buyers, 180d2 · 74 pct, sector of 142
Institutional and government
57
Inputs
  • Funds adding, latest quarter80 · 57 pct, sector of 191
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
40
Inputs
  • Short interest, % of float+12.3% · 13 pct, sector of 241
  • Recalls per $1B revenue, 3y0.00 per $1B · 100 pct, sector of 116
  • EPA cases per $1B revenue, 5ynot measured for this sector, almost no peer has an event
  • New text in Risk Factors, latest 10-K+28.6% · 7 pct, sector of 198
1 not measured: US patents
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

QTRX filings, in plain words

Are Quanterix insiders buying or selling QTRX?

In the 180 days to 2026-10-28, Quanterix insiders were net buyers, a net $296.0K across purchases and sales reported on Form 4, by 2 buyers.

Read the full summary

In the 180 days to 2026-10-28, Quanterix insiders were net buyers of QTRX, a net $296.0K across purchases and sales reported on Form 4 by 2 buyers. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies